1
Q
trade name
A
Lipitor
2
Q
class
A
- HMG CoA reductase inhibitor
- antilipemic
3
Q
action
A
- ↓ LDL
- ↓ VLDL
- ↑ HDL
- other
- promotes vasodilation
- ↓ in plaque inflammation
- ↓ risk of thromboembolism
4
Q
use
A
- primary hypercholesterolemia (↑ HDL)
- prevention of coronary events (primary or secondary)
- protection against MI and stroke for DM pts
5
Q
complications
A
- hepatotoxicity (↑ AST)
- myopathy
6
Q
S/Sx of myopathy
A
- aches
- pain
- tenderness
- may progress to myositis or rhabdomyolysis
7
Q
interventions for hepatotoxicity
A
- LFTs: baseline, @ 12 wks, q 6 months
- monitor for liver dysfunction
- anorexia
- N&V
- jaundice
- notify provider
- avoid ETOH
- D/C for abnormal LFTs
8
Q
interventions for myopathy
A
- CK level: baseline, periodic
- report muscle aches, pain, tenderness
- D/C if CK elevated
9
Q
contraindications
A
- pregnancy (X)
- viral or ETOH-induced hepatitis
10
Q
precautions
A
- older adults
- debilitated condition
- chronic renal dz
11
Q
interactions
A
- fibrates
- meds that suppress CyP3A4
- grapefruit juice
12
Q
fibrates + atorvastatin =
A
- ↑ risk of myopathy
- monitor CK level
13
Q
CyP3A4-suppressing drugs or grapefruit juice + atorvastatin =
A
- ↑ level of statin
- avoid concurrent use
- ↓ dose of statin
- do not drink grapefruit juice
14
Q
meds that suppress CyP3A4
A
- erythromycin
- ketonconazole
- grapefruit juice
15
Q
admin
A
- PO
- with or without food
- evening dose (most cholesterol synthesized at night)
- appropriate in renal insufficiency
- monitor LFTs and lipid panel
2021 Pharm 2
flashcards
Decks in class (18)
# Cards
